NYSE - Delayed Quote USD

Allurion Technologies Inc. (ALUR)

2.8600

+0.0100

+(0.35%)

At close: June 4 at 4:00:02 PM EDT

2.7800

-0.08

(-2.80%)

Pre-Market: 5:55:44 AM EDT

Allurion to Present at Jefferies Global Healthcare Conference

NATICK, Mass., May 29, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET.

Business Wire 6 days ago

ALUR
+0.35%

ALUR-WS
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results

Allurion Technologies Inc. (NYSE:ALUR), a leader in innovative weight loss solutions, is set to resume patient treatments in France next month following the successful resumption of product shipments. This announcement comes on the heels of new clinical data presented at the SOFFCO.MM meeting in Saint-Etienne, France. The study evaluated 1,962 French patients using Allurion Technologies […]

Insider Monkey 8 days ago

ALUR
+0.35%

ALUR-WS
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

NATICK, Mass., May 27, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l’Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025.

Business Wire 8 days ago

ALUR
+0.35%

ALUR-WS
Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

Allurion Technologies Inc (ALUR) reports significant operational improvements and strategic progress despite a dip in revenue due to temporary market suspensions.

GuruFocus.com 21 days ago

ALUR
+0.35%

ALUR-WS
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

NATICK, Mass., May 14, 2025--Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update.

Business Wire 21 days ago

ALUR
+0.35%

ALUR-WS
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

NATICK, Mass., May 13, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass pre

Business Wire 22 days ago

ALUR
+0.35%

ALUR-WS
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

NATICK, Mass., May 05, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Business Wire 30 days ago

ALUR
+0.35%

ALUR-WS
Allurion Announces Postponement of Special Meeting of Stockholders

NATICK, Mass., April 03, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM

Business Wire 2 months ago

ALUR
+0.35%

ALUR-WS
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

NATICK, Mass., March 26, 2025--Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

Business Wire 2 months ago

ALUR
+0.35%

ALUR-WS
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass., March 20, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.

Business Wire 2 months ago

ALUR
+0.35%

ALUR-WS
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

NATICK, Mass., March 12, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

Business Wire 2 months ago

ALUR
+0.35%

ALUR-WS
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass., March 04, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled "Automatic-Sealing Balloon-Filling Catheter System" and U.S. Patent No. 12,245,962 titled "Balloon Sealing and Fill Valve". These patents, both of which are scheduled to issue on March

Business Wire 2 months ago

ALUR
+0.35%

ALUR-WS
Allurion to Participate in Upcoming Investor Conferences

NATICK, Mass., February 25, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.

Business Wire 3 months ago

ALUR
+0.35%

ALUR-WS
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass., February 20, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of common stock in a concurrent private placement. The warrants have an exercise price

Business Wire 3 months ago

ALUR
+0.35%

ALUR-WS
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass., February 19, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share in a registered direct offering. In addition, the Company will issue to the investors warrants to purchase up to 1,800,000 shares

Business Wire 3 months ago

ALUR
+0.35%

ALUR-WS
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

NATICK, Mass., February 18, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy.

Business Wire 3 months ago

ALUR
+0.35%

ALUR-WS
Allurion Relaunches in France

NATICK, Mass., February 13, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales.

Business Wire 3 months ago

ALUR
+0.35%

ALUR-WS
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 3 months ago

ALUR
+0.35%

ALUR-WS
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investor's Business Daily 4 months ago

NONOF

NVO

ALUR
+0.35%
Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement

The stock rally followed news of a planned study combining the Allurion Program with GLP-1 therapies.

GuruFocus.com 4 months ago

ALUR
+0.35%

ALUR-WS

Performance Overview

Return	ALUR	S&P 500 (^GSPC)
YTD	-73.40%	+1.52%
1-Year	-92.42%	+12.84%
3-Year	-98.83%	+45.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Allurion Technologies Inc. (ALUR)

Allurion to Present at Jefferies Global Healthcare Conference

Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

Allurion Announces Postponement of Special Meeting of Stockholders

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion to Participate in Upcoming Investor Conferences

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Allurion Relaunches in France

How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement

Performance Overview